• Rui Han, Qianqian Yu, Guohui Zhang, Baoqiang Li, Shuzhen Han, and Guiying Li.
• Rui Han, Department of Pediatrics (I), Binzhou People's Hospital, Shandong, 256610, China.
• Pak J Med Sci. 2020 Jan 1; 36 (2): 156-159.

ObjectiveTo study and compare the clinical effects of azithromycin and erythromycin on children with mycoplasma pneumonia.MethodsTotal 132 children with mycoplasma pneumonia who were admitted to our hospital between November 2017 and September 2018 were selected as the research subjects. All the children were divided into an observation group and a control group according to random number table, 66 each. The observation group was treated with azithromycin, while the control group was treated with erythromycin. The therapeutic effect, incidence of adverse reactions and disappearance time of clinical symptoms were compared between the two groups.ResultsThe total efficacy of the observation group was 98.04%, and that of the control group was 74.51%; there was a significant difference (X2=7.184, P=0.007). The incidence of adverse reactions in the observation group was 15.69%, significantly lower than that in the control group (41.18%) (X2=6.376, P=0.002). The disappearance of fever, cough, rale and X ray shadow of the observation group was significantly earlier than that of the control group, and the difference was statistically significant (P<0.05).ConclusionCompared with erythromycin, azithromycin is more effective in the treatment of mycoplasma pneumonia in children. Azithromycin can further shorten the improvement time of clinical symptoms and signs and has few adverse reactions and high safety. It is worth clinical application.Copyright: © Pakistan Journal of Medical Sciences.

5 keywords...

hide…